Not sure I am required to post who I am with, since I live in Canada. But, just in case:
https://www.cppinvestments.com
^
I have a personal position here. But, like me, this organization uses investment companies for $OCGN type stock.
Man Davies
Posts (4982)
If you could see my position, you would know why. I am going BIG on $OCGN. All I can say is that I have > 150,000 and < 2M. I dont want to say, cause most big investors have to report. But, my buys are spread out over 15 to 30 different investment companies, as part of a bigger portfolio. I enjoy posting cause, it makes me feel relevant. :)
A lot of the traders are thinking quick turnaround of 10 min. to 10 days. I am set for 3-24 months.
A sell for 1/3 shares at $23
Pumpthedump<- No stop loss here. I have a sell order, for 1/3 of my shares, set at $23
Here is WHY I believe Bausch will go after Ocugen:
*
Bausch partnered with Eton Pharmaceuticals to develop a conjunctivitis drug, and, the partnership failed. What is Bausch but an eye company that has FAILED to develop ANY NEW eye drugs:
https://www.bausch.com/our-company/about-bausch-lomb
The suite of Ocugen eye drugs treat a range of eye conditions from dry eye to gene therapy (with prior and pending FDA approvals). Ocugen is EXACTLY the type of company Bausch would target for partnership or buyout.
https://ocugen.com/pipeline/ocunanoe-ocugens-one-platform/
https://ocugen.com/pipeline/ocu200/
https://ocugen.com/pipeline/ocu300/
https://ocugen.com/pipeline/ocu400/
https://ocugen.com/pipeline/ocu410/
https://noble.mediasite.com/Mediasite/Play/9e397dbe17174ae0b92901fcc40988871d
https://ir.ocugen.com/node/8476/pdf
Finally, as this google search reveals, Bausch is not afraid to partner with other companies:
As this list reveals, Bausch is also NOT afraid to buy a company OUT, to get their drugs:
;)
My own gut instinct is that Bausch is a prime candidate to acquire Ocugen. Not sure if you have seen me post on other boards, but, given my heavy acquisition experience, over the past 33 years of trading, I have correctly identified 76 buyouts, before they actually occurred. Just last week, I made a call that Bezos would go after JCP and HE DID. I have made correctly similar calls around the boards in the past.
My own gut instinct is that Bausch is a prime candidate to acquire Ocugen. Not sure if you have seen me post on other boards, but, given my heavy ac
Personally, I am liking the buyout attractiveness here. Ocugen is getting a lot of good press. Having been on one for 15 years, for a Fortune 12 Pharma, Acquisition Teams rely heavily on Zacks Premium
analysis. And, Zacks is EXTREMELY BULLISH on Ocugen.